Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

MyoKardia Inc (MYOK) USD0.0001

Sell:$62.44 Buy:$62.76 Change: $1.98 (3.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.98 (3.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.98 (3.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Contact details

333 Allerton Ave
United States
+1 (650) 7410900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.97 billion
Shares in issue:
46.23 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Tassos Gianakakos
    President, Chief Executive Officer, Director
  • Taylor Harris
    Chief Financial Officer
  • William Fairey
    Executive Vice President and Chief Commercial Officer
  • June Lee
    Executive Vice President, Chief Development Officer
  • Joseph Lambing
    Senior Vice President - Nonclinical and Pharmaceutical Development
  • Robert McDowell
    Senior Vice President - Drug Discovery
  • Cynthia J. Ladd
    General Counsel
  • Jake Bauer
    Chief Business Officer
  • Marc Semigran
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.